SMARCA1 and neoplasm: Understanding the direct oncogenic mechanisms by which BRG1 is contributing to tumour development, whether that be via dysregulation of specific transcriptional programs, abnormal SWI/SNF complex recruitment and targeting, or an impaired DNA damage response, will guide treatment development in the most effective way.